[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

The sponsorship helps expand proven Alpha-1 detection strategies, which will enable earlier patient identification

SAN : 12.28 (+0.82%)
SNY : 43.31 (+0.30%)
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%

Dividends are on the rise at Costco, Sanofi, and SAP, three of the world's largest companies with market capitalizations above $100 billion.

COST : 1,008.79 (-0.32%)
SAP : 173.70 (-0.58%)
WMT : 130.43 (+0.18%)
SNY : 43.31 (+0.30%)
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin...

SAN.FP : 73.100 (-0.87%)
REGN : 714.89 (+0.82%)
SNY : 43.31 (+0.30%)
Sanofi's Pipeline Downgrades Suggest Thursday's Beat Won't Matter

Barchart Research What to Expect from SNY Earnings SNY Generated April 22, 2026 Current Price $46.90 EPS Estimate $$1.06 Consensus Rating Moderate Buy Average Move 3.92% Sanofi's Pipeline Downgrades Suggest...

SNY : 43.31 (+0.30%)
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

SAN.FP : 73.100 (-0.87%)
REGN : 714.89 (+0.82%)
SNY : 43.31 (+0.30%)
Sanofi announces leadership evolution in Specialty Care Business Unit

CAMBRIDGE, Mass. , Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard,...

SAN : 12.28 (+0.82%)
SNY : 43.31 (+0.30%)
Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

JNJ : 221.32 (-0.53%)
LLY : 948.45 (-2.72%)
ABBV : 201.55 (-0.57%)
GSK : 50.41 (-0.18%)
CSLLY : 21.7100 (-0.46%)
PFE : 25.68 (-1.42%)
SNY : 43.31 (+0.30%)
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX

NEW YORK and NEW ORLEANS , Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating...

DVAX : 15.50 (unch)
SNY : 43.31 (+0.30%)
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Dynavax Technologies Corporation...

DVAX : 15.50 (unch)
SNY : 43.31 (+0.30%)
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent...

SAN.FP : 73.100 (-0.87%)
REGN : 714.89 (+0.82%)
SNY : 43.31 (+0.30%)

Barchart Exclusives

Palantir Stock Has a ‘High-Class Problem’: Demand for Its Software Is Far Outpacing Supply
Palantir’s greatest challenge may no longer be demand, but how quickly it can deliver AI software to customers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.